share_log

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Capricor Therapeutics预计,可用现金及等价物将足以支付2025年第一季度的预期支出和资本需求
Benzinga ·  05/13 16:20

Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025

Capricor Therapeutics预计,可用现金及等价物将足以支付2025年第一季度的预期支出和资本需求

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发